JAKARTA, Indonesia (AP) – Indonesian President Joko Widodo on Wednesday received the first shot of a Chinese-made COVID-19 vaccine after Indonesia approved it for emergency use and began efforts to vaccine millions of people in the world’s fourth most populated country.
Conditional use of the Sinovac Biotech Ltd. vaccine is scheduled to be rolled out in the coming months with health care workers, civil servants and other at-risk populations prioritized first. It will be free for all Indonesian citizens.
Budi Gunadi Sadikin, Indonesia’s health minister, said the country needs to vaccinate 181.5 million people, or roughly 67% of its population, to reach herd immunity. That means the two-shot vaccine would require almost 427 million doses, including the estimated 15% wastage rate.
But distribution will not be easy in the vast archipelago where transportation and infrastructure are inadequate in places. Health officials have cited concerns about keeping the vaccine refrigerated at the required 36–46 degrees Fahrenheit to maintain its safety and effectiveness.
“We know that the cold-chain distribution is not complete. This is the obstacle,” Sadikin said Tuesday. “The cold-chain facilities are not enough so we are still distributing some of the vaccines. We are worried.”
Indonesia received its first shipment of the Sinovac vaccines on Dec. 6 and locked it in cold storage surrounded by armed guards. Authorities began distributing the vaccines to key locations around the country while awaiting emergency use authorization.
The vaccine was cleared for emergency use based on clinical trial data and after the country’s highest Islamic clerical body declared the vaccine holy and halal.
Indonesia’s vaccination program is the first large-scale use of the Sinovac vaccine outside of China.
Indonesia has recorded more than 846,000 cases of the virus, including over 24,600 deaths.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Copyright © 2021 The Washington Times, LLC.
View original Post